ライフサイエンスコーパス: ischemic time

1 uch arguments and find ways to shorten total ischemic time.

2 nd these factors were related to duration of ischemic time.

3 portal venous lactate concentration and cold ischemic time.

4 ns with significantly longer total allograft ischemic time.

5 tion Network) could be associated with total ischemic time.

6 d multivariable regression adjusted for warm ischemic time.

7 ion of some of these lncRNAs correlates with ischemic time.

8 ter matching donor quality and adjusting for ischemic time.

9 provement in clinical outcomes regardless of ischemic time.

10 t of retrieval, and so does not include cold ischemic time.

11 y after coronary reperfusion associates with ischemic time.

12 titis C virus + serology, donor age and cold ischemic time.

13 group, donor-recipient size differences, or ischemic time.

14 en eligible for organ donation based on warm ischemic time.

15 ransplantation and cases with prolonged cold ischemic time.

16 der cardiopulmonary resuscitation, and total ischemic time.

17 hour without ventilation, defining the warm ischemic time.

18 ed leading to a potential reduction in total ischemic time.

19 to abrogate IRI when subjected to increasing ischemic times.

20 ive field in order to prevent prolonged warm ischemic times.

21 ar efficacy in kidney preservation at longer ischemic times.

22 inal donors or organs experiencing prolonged ischemic times.

23 ansplant outcomes, in contrast to subsequent ischemic times.

24 allografts experienced longer total and warm ischemic times.

25 ic transplants and cases with prolonged cold ischemic times.

26 splants (1.556, P<0.01), with prolonged cold ischemic time (1.097, P=0.03), for black recipients (1.2

27 .44 vs. 3.12+/-0.36 hr, P<0.05) and the warm ischemic time (1.23+/-0.54 vs. 3.91+/-0.53 min, P<0.05).

28 59, P < 0.001) and reduction in median cold ischemic time (10 vs. 6 h, P = 0.001).

29 D group were biopsy findings (38%), DCD warm ischemic time (11%), and prolonged preservation time (10

30 ary graft dysfunction was the asystolic warm ischemic time: 15 (12-17) versus 13 (11-14) min ( P < 0.

31 x (1.83 vs. 1.32, p < .001), and longer cold ischemic time (16.5 vs. 14.8 h, p = .03).

32 ibrillation (81% vs 46%; p < 0.001), shorter ischemic time (18.9 vs 26.4 min; p = 0.003), more witnes

33 er liter; P<0.0001) despite having identical ischemic times (185+/-8 minutes versus 181+/-5 minutes;

34 ate (182.88 +/- 69.80 vs. 221.31 +/- 56.91), ischemic time (187.4 +/- 63.1 vs. 215.5 +/- 68.1), and d

35 tation (8.6 vs 7.0 min; p < 0.001) and total ischemic time (25.6 vs 22.3 min; p < 0.001) and less oft

36 vs. 47 years), donor age (29 vs. 28 years), ischemic time (3.0 vs. 2.9 hr), and pretransplant medica

37 ist (15 versus 35 days, P<0.001), had longer ischemic times (3.5 versus 3.0 hours, P<0.001), and rece

38 cold ischemic time was 219 minutes and warm ischemic time 46 minutes.

39 TA-NRP donors had shorter median (IQR) lung ischemic times (6.07 [4.38-9.56] hours vs 8.12 [6.16-12.

40 of graft loss per hour increase in the total ischemic time (adjusted hazard ratio, 1.09; 95% confiden

41 Higher volume TXCs exhibited lower total ischemic times after the removal of DSA from lung alloca

42 chemia time greater than 30 minutes and cold ischemic time also occurred over the same period.

43 The interaction between ischemic time and alteplase dose was statistically signi

44 , anastomotic time (P=0.0012), combined cold ischemic time and anastomotic time (P=0.00018), and body

45 analyses accounting for the effects of cold ischemic time and donor age, Treg suppressive function d

46 c subgroup analyses were performed for total ischemic time and first medical contact (FMC)-to-device

47 performed to assess the association of total ischemic time and FMC-to-device time with CV mortality a

48 In the current STEMI era, both total ischemic time and FMC-to-device times continue to be imp

49 tors were LTx from a female donor, prolonged ischemic time and number of perioperative red blood cell

50 ociated with first transplants, shorter cold ischemic time and operative time, and less intraoperativ

51 Prolonged cold ischemic time and recipient life support were predictors

52 is associated with substantial reductions in ischemic time and treatment delays.

53 on change was largely attributable to longer ischemic times and patient acuity.

54 rgery, and concerns continue about prolonged ischemic times and risk of bleeding in various MIS setti

55 nd severity of injury, vascular examination, ischemic times) and operative (methods of arterial repai

56 usted for year of transplant, donor quality, ischemic time, and candidate status.

57 r pulmonary vascular resistance index, graft ischemic time, and cardiopulmonary bypass time, donor lo

58 ty, increased cardiopulmonary bypass time or ischemic time, and circulatory arrest; and postoperative

59 edema, donor/recipient HLA-DR mismatch, cold ischemic time, and donor age were independently associat

60 nces in the first warm ischemic period, cold ischemic time, and donor age.

61 ed organs from younger donors, had a shorter ischemic time, and had a higher frequency of sex mismatc

62 SN group, recipients were older, with longer ischemic time, and higher distance ( P <0.001 for all co

63 ive antibody, donor types, donor creatinine, ischemic time, and immunosuppression regimens.

64 ioplegia volume per anastomosis or minute of ischemic time, and less hot-shot use.

65 decreased bleeding, reduced liver allograft ischemic time, and may result in reduced rates of graft

66 Donor age, sex, cold ischemic time, and NMP time did not correlate with IL-6

67 Increased transfusion burden, longer cold ischemic time, and non-White recipients were associated

68 In contrast, donor asystolic time, cold ischemic time, and reperfusion time were independently a

69 cluded older age at transplant, shorter cold ischemic time, and single strictures.

70 , blood product use, primary diagnosis, cold ischemic time, and surgeon were similar between the grou

71 ease, diabetes status, body mass index, cold ischemic time, and UNOS status.

72 ificantly younger female recipients, shorter ischemic time, and younger female donors compared with t

73 are very promising, demonstrating short warm ischemic times, and a low rate of complication and recur

74 s, primary diagnosis, surgeon, warm and cold ischemic times, and blood product use were recorded.

75 n/fraction of inspired oxygen ratios, longer ischemic times, and longer travel distances.

76 lder recipient age, older donors with longer ischemic times, and pre-HT Fontan operations.

77 y Donor Profile Index strata, increased cold ischemic times, and shorter distance traveled.

78 toward the use of older donors, longer graft ischemic times, and shorter waitlist durations.

79 y of poor ex vivo perfusion, had longer cold ischemic times, and were transplanted into older recipie

80 thmias, the bicaval technique and minimizing ischemic time are current surgical standards.

81 Pre-transplant VAD and prolonged ischemic times are more important determinants of PGD.

82 identified younger age and longer donor warm ischemic time as risk factors for homograft failure and

83 dema after lung transplantation, with longer ischemic times associated with greater permeability to p

84 circulatory death livers with extended cold ischemic time at 10 degrees C demonstrates superior allo

85 Mean warm ischemic time at recovery in the DCD group was 17.8 +/-

86 e effect of long (n = 16) and short (n = 12) ischemic times (average of 6 h and of 73 min, respective

87 Due to unavoidable prolonged ischemic time before procurement in donation after cardi

88 relevant endpoints across a spectrum of warm ischemic times, before and during ex vivo heart perfusio

89 These differences occurred despite total ischemic time being significantly longer in the long-int

90 Ischemic time between arterial ligation and ILP was 226

91 The finding of similar fractions of ischemic time between awake and sedated states persisted

92 ercutaneous coronary intervention with known ischemic times between 1 and 6 hours identified 165 pati

93 irst ST-elevation myocardial infarction with ischemic times between 1 and 6 hours who received primar

94 hrombolysis in myocardial infarction=0) with ischemic times between 1 and 6 hours with no evidence of

95 etransplantation), bypass times, and cardiac ischemic times between the two groups.

96 Increased cold ischemic time but neither donor age nor intensity of ino

97 and to limit the detrimental impact of warm ischemic time by perfusing organs in situ following the

98 ntigen mismatches (chi-square 3.06) and cold ischemic time (chi-square 3.23).

99 9 renal transplants were performed with cold ischemic times (CI) greater than 16 hr (UW 87, HTK 62) a

100 n 30% versus 35%, P < 0.001) but longer cold ischemic time (CIT) (median 21.0 h versus 18.6 h, P < 0.

101 also examined the relationship between cold ischemic time (CIT) and likelihood of surgical complicat

102 Total cold ischemic time (CIT) consisted of the time from retrieval

103 Multivariate analysis revealed that cold ischemic time (CIT) greater than 8 hours (HR: 2.46; P =

104 We stratified on basis of cold ischemic time (CIT) to determine the interaction of pres

105 Mean cold ischemic time (CIT) was 5.4 hours in O and 7.3 hours in

106 The degree of HLA matching, the cold ischemic time (CIT), the balance of exchange, and graft

107 Long cold ischemic time (CIT), with or without delayed graft funct

108 lsatile perfusion (PP) across different cold ischemic times (CIT) within different donor groups is un

109 e heart transplant was completed first (cold ischemic time [CIT]: 131 minutes), followed by the liver

110 ition centers saw an 18.5-minute increase in ischemic time compared to low competition centers (P = .

111 ients in the SAC group had longer myocardial ischemic time compared with those in the PAC group (mean

112 erved in the Celsior group despite prolonged ischemic times compared with LPD.

113 opsies collected at the beginning and end of ischemic time (cross-clamp time).

114 Ischemic time, defined as the time from symptom onset to

115 iabetes, body mass index, waiting time, cold ischemic time, delayed graft function, and coronary risk

116 erences as dramatic as those associated with ischemic times, despite uniform protein expression profi

117 ls during sedative interruption, fraction of ischemic time did not differ between the time awake vs.

118 not long-term, graft survival, whereas cold ischemic time did not have statistically significant ass

119 avenous glycoprotein IIb/IIIa inhibitors and ischemic time did not seem to influence any potential be

120 ge, donor-to-recipient size differences, and ischemic time do not contribute to differences in expect

121 regards to recipient age, recipient gender, ischemic time, donor age, and donor gender.

122 was a significant interaction between total ischemic time, donor age, and graft loss (P value for in

123 iate logistic regression accounting for cold ischemic time, donor age, previous transplant, and pretr

124 lant variables associated with PGF included: ischemic time, donor gender, donor age, multiorgan donat

125 As warm ischemic time exposure increased in DCD groups, fewer he

126 he association between transit time and cold ischemic time for adult, deceased kidney transplant dono

127 volume and closeness centrality, with total ischemic time for deceased donor lung transplants in con

128 dualized score procedure was used to correct ischemic time for each patient's simultaneously measured

129 ctive, pooled cross-sectional study of total ischemic time for nonperfused deceased donor lung transp

130 e between the two groups with regard to cold ischemic time for organ storage, donor age, recipient ag

131 The allograft warm ischemic time for the laparoscopic cases was 4.2+/-1.3 m

132 Ischemic times for heart (OLD, 2.94 versus NEW, 3.37 hou

133 The mean cold ischemic times for the kidney and the pancreas were 15+/

134 16 nautical miles, with an increase in total ischemic time from 3 to 3.4 hours (all P < .001).

135 ally and shared nationally, livers with cold ischemic time >12 hours, livers from hepatitis C virus p

136 raction, shock at the time of admission, and ischemic time >25 minutes) of 0 to 5 was: 7.1% versus 10

137 gment elevation myocardial infarction and an ischemic time >=4 to 6 h, adjunctive treatment with low-

138 However, in patients with an ischemic time >=4 to 6 h, alteplase increased the mean e

139 In a multivariable analysis, both total ischemic time (>2 hours: HR, 1.26 [95% CI, 1.00-1.58) an

140 Pre-transplant VAD and prolonged total ischemic times (> or = 4.5 hours) were independent predi

141 antibodies (PRAs) (>20%), and prolonged cold ischemic times (>24 hours) in each group.

142 teen children received organs with prolonged ischemic times (>8 hours)(PIT) compared with 14 with sho

143 Prolonged donor warm ischemic time has been identified as the key factor resp

144 on graft outcomes, such that the duration of ischemic time has the greatest impact on graft survival

145 Patients with shorter ischemic times have a greater viable myocardium and may

146 dependence on marginal grafts with prolonged ischemic times have meant that new methods are needed to

147 were MVO (hazard ratio, 3.418; P=0.046) and ischemic time (hazard ratio, 1.016; P<0.001).

148 between transplant eras was attenuated, but ischemic time (hazard ratio, 1.16 [95% CI, 1.07-1.26]; P

149 ive blood loss, surgical reexploration, long ischemic times, immediate postoperative cardiovascular d

150 Expression levels of IL-8 correlate with the ischemic time imposed on the renal graft.

151 The cold and warm ischemic times improved significantly during the second

152 o-touch period and 41 min of functional warm ischemic time in a DCD donor after the preconditioning p

153 Concern exists that donor warm ischemic time in addition to subsequent cold ischemia-re

154 nd graft loss, cause of graft loss, and cold ischemic time in the geriatric population.

155 -0.75]; P=0.009), despite an increased total ischemic time in the SherpaPak group.

156 Total ischemic time (in hours) was defined as the time of the

157 Donor ischemic time increased from 150 to 166 minutes (P < .00

158 in recipients with LVADs may produce longer ischemic times, innovations in donor heart preservation

159 to examine whether older donor age and cold ischemic time interact to produce inferior allograft sur

160 Avoiding grafts with ischemic time (IT) >6 hours continues to be advised in p

161 outcomes, despite prolonged total allograft ischemic time, it may be reasonable to adopt the SherpaP

162 ariables including demographics, donor type, ischemic time, kidney donor profile index, and pancreas

163 ed odd of DGF compared with those with total ischemic time less than 14 hours.

164 Long ischemic times (LIT) led to significantly (p < 0.05) gre

165 n two episodes of acute rejection, and organ ischemic time longer than 180 minutes.

166 gh lactate levels are associated with longer ischemic times, longer duration of inotrope, and corresp

167 isolations (donor age 41-59, BMI 26-38, cold ischemic time < 10 h).

168 nfarction study that enrolled 1099 patients (ischemic time <6 hours) in Italy, Scotland, and China.

169 s index <35, non-status 1 registration, cold ischemic time <8 hours, and either hepatocellular carcin

170 ome, there was no benefit based on (1) total ischemic time (<2 hours: hazard ratio [HR], 0.77 [95% CI

171 (>8 hours)(PIT) compared with 14 with short ischemic times (< or =90 minutes)(SIT).

172 t was more pronounced in patients with short ischemic times (<2 hours: odds ratio [OR], 0.23 [95% CI,

173 survival: donor and recipient demographics, ischemic time, LVAD, retransplantation, pretransplant pu

174 Donor warm ischemic time may predispose hepatic allografts to an in

175 ere less than 2 minutes, because longer warm ischemic times may make the use of heparin a more import

176 they are typically young and have short cold ischemic times, may be advantageous for HCV-infected pat

177 low esophageal temperature but not cerebral ischemic time (mean 32 minutes).

178 ting, waiting time (mean, 1.3 months), graft ischemic time (mean, 228 minutes; range, 68 to 479 minut

179 median 30% vs. 35%, p<0.001) but longer cold ischemic time (median 21.0 hours vs. 18.6, p<0.001).

180 %, P < .001), despite a slightly longer cold ischemic time (median: 14.8 vs 14.1 hours, P < .001).

181 ravenous glycoprotein IIb/IIIa inhibitors or ischemic time might modify any clinical benefits observe

182 rtery injury include blunt trauma, prolonged ischemic times, musculoskeletal injuries, and venous dis

183 pulmonary vascular resistance index), donor ischemic time, occurrence of postoperative infections, e

184 Recipients with total ischemic time of 14 hours or longer experienced an incre

185 situ cardioplegic arrest was followed by an ischemic time of 3 or 6 hr, transplantation, and blood r

186 d criteria deceased donor kidneys with total ischemic time of less than 12 hours (SCD, <12), SCD of 1

187 ia/reperfusion injury by prolonging the cold ischemic time of the allograft did not affect the severi

188 achieved, age and gender of the donor, cold ischemic time of the graft, and matching of CMV serologi

189 ime was 430 minutes (393-480), cold and warm ischemic times of 85 (32-136) and 37.5 (31-47) minutes.

190 Cold ischemic times of both pancreas and kidneys were longer

191 before implantation, aiming to achieve short ischemic times off NMP.

192 l's solution was associated with longer cold ischemic time, older donors, kidney-only donors, donors

193 We see little effect of cold ischemic time on cell yield, total number of reads per c

194 r age, the pathway of donor death, and total ischemic time on graft outcomes, such that the duration

195 ath and rejected due to prolonged donor warm ischemic times; one liver from a brain-death donor was d

196 Ischemic time (OR = 1.04, P = 0.008) and being in the IC

197 AD, immunosuppression, sex, donor age, donor ischemic time, or cytomegalovirus between the two groups

198 megalovirus (CMV) status or blood type, cold ischemic times, or the incidence of outflow obstruction.

199 owed little development of OB, regardless of ischemic time (p < 0.05).

200 increased volumes exhibited lower levels of ischemic time (P <= 0.001).

201 ion policy, exhibited higher levels of total ischemic time (P <= 0.001).

202 infection (4.9%, P = 0.001) and longer cold ischemic time (P = 0.001).

203 y exhibited u-shaped associations with total ischemic time (P = 0.012; P = 0.006) and the effect of c

204 tion (p =.029) and inversely with graft cold ischemic time (p =.007).

205 ve transfusion requirements (P=0.0001), cold ischemic time (P<0.0001), use of roux-en-Y biliary anast

206 death (P=0.0053), donor age (P=0.0017), cold ischemic time (P=0.0009), anastomotic time (P=0.0012), c

207 ery thrombosis (P=0.0018) and prolonged cold ischemic time (P=0.034), were independent risk factors a

208 =0.17, 0.70, and 0.50, respectively) or with ischemic time (P=0.29, 0.66, and 0.58, respectively).

209 sed 2/2 PAI-1 genotyped allograft had longer ischemic times (P=0.02) than those recipients with a Tx

210 ype (DCD vs DBD), donor age, steatosis, cold ischemic time, peak aspartate transaminase, day 5 biliru

211 However, total ischemic time per 24 hours (15.0 +/- 21.4 versus 23.6 +/

212 21.4 versus 23.6 +/- 31.1 minutes, P = .02), ischemic time per episode (6.3 +/- 4.6 versus 9.0 +/- 8.

213 del adjusting for HCV-Donor Risk Index, warm ischemic time, pretransplant Model for Endstage Liver Di

214 , mean +/- standard error) compared to short ischemic times (ratio = 0.19 +/- 0.05).

215 s independently associated with PGD included ischemic time, recipient African American race, and reci

216 ents myocardial functional recovery after an ischemic time relevant to clinical cardiac transplantati

217 is report, we show that a modest increase in ischemic time results in conversion from a CD18-dependen

218 evity include younger age, longer donor warm ischemic time, smaller homograft size, use of aortic hom

219 Work should continue to focus on reducing ischemic times so EVLP can continue to increase the dono

220 acy of myocardial reperfusion, including the ischemic time, ST-segment elevation, angiographic blush

221 ungs placed on EVLP had significantly longer ischemic time than No EVLP ( P < 0.001).

222 rminal creatinines and shorter pancreas cold ischemic times than DBD donors.

223 The MA group had longer operative and ischemic times than SA group.

224 After adjusting for hospital status and ischemic time, there was no association between the EVLP

225 The mean ischemic time to 50% myoglobin desaturation was, on aver

226 dding the donor-related variables of age and ischemic time to the model improved its performance in b

227 The total ischemic time to the organ was 50 minutes.

228 However, the contribution of ischemic time to this process remains unknown.

229 gender, type of LT, indication for LT, graft ischemic time, use of cardiopulmonary bypass, cytomegalo

230 is identified younger age, longer donor warm ischemic time, valve Z: value <2, and previous procedure

231 If cold ischemic time was > or =24 hr, there was a 2.19-fold inc

232 The median cold ischemic time was 1.6 hours (IQR: 1.0-2.3 hours) with 88

233 Mean cardiac ischemic time was 140 +/- 45 minutes.

234 The mean functional warm ischemic time was 15 min (SD 6 min)' and the median dura

235 The mean cold ischemic time was 16.5 hr in the two-layer group versus

236 Average donor ischemic time was 217 min.

237 The cold ischemic time was 219 minutes and warm ischemic time 46

238 Total ischemic time was 7.9 hr for both groups.

239 the effect of closeness centrality on total ischemic time was different after DSA removal (P < 0.001

240 Mean warm ischemic time was limited at 238 +/- 112 seconds.

241 Mean cold ischemic time was longer in DKT (22.2+/-9.7 hr), but rat

242 Warm ischemic time was longer in the HA group (mean [SD] HA 5

243 and abdominal wall transplantation where the ischemic time was minimized by remotely revascularizing

244 Graft ischemic time was positively correlated with the degree

245 The total ischemic time was significantly longer for ECMO-rescued

246 Cold ischemic time was significantly longer in patients who r

247 The cumulative ischemic time was similar for the two groups ([mean +/-

248 Mean ischemic time was slightly but not significantly higher

249 The effects on total ischemic time were dependent on whether DSA was used for

250 , body mass index, creatinine clearance, and ischemic time were independently associated with overall

251 estive heart failure, donor age and sex, and ischemic time were recorded.

252 Lower donor age and ischemic time were significantly positively associated w

253 It is important to note that our warm ischemic times were less than 2 minutes, because longer

254 Mean bypass and ischemic times were significantly longer in patients wit

255 Cold ischemic times were similar between groups, but more ECD

256 Warm and cold ischemic times were typically <45 min and <90 min, respe

257 nor cause of death, recipient diagnosis, and ischemic time) were mostly balanced between the groups.

258 y, decreasing operative times, and allograft ischemic times, whereas offering protection of implanted

259 16 to 1.34) in kidneys with total donor warm ischemic time (WIT) of 10-26 minutes to 2.67 (95% CI, 2.

260 (n=5) underwent left nephrectomy after warm ischemic times (WIT) of 0 or 30 min.

261 , we examined the relationship between total ischemic time with graft outcomes among recipients who r

262 eritransplant conditions, such as shortening ischemic times with the use of thrombolytic donor flush,

263 ars included increasing donor age, prolonged ischemic time, worsening recipient creatinine, recipient